Burris-Hiday S, Scott E
J Biol Chem. 2023; 299(9):105112.
PMID: 37517692
PMC: 10481364.
DOI: 10.1016/j.jbc.2023.105112.
Danel T, Wojtuch A, Podlewska S
Comput Struct Biotechnol J. 2022; 20:5639-5651.
PMID: 36284709
PMC: 9582735.
DOI: 10.1016/j.csbj.2022.10.005.
Huff H, Vasan A, Roy P, Kaul A, Tajkhorshid E, Das A
Biochemistry. 2021; 60(37):2749-2760.
PMID: 34491040
PMC: 8455456.
DOI: 10.1021/acs.biochem.1c00158.
Nigam A, Pollice R, Krenn M, Dos Passos Gomes G, Aspuru-Guzik A
Chem Sci. 2021; 12(20):7079-7090.
PMID: 34123336
PMC: 8153210.
DOI: 10.1039/d1sc00231g.
McCarty K, Ratliff S, Furge K, Furge L
Drug Metab Dispos. 2020; 49(3):179-187.
PMID: 33376147
PMC: 7883074.
DOI: 10.1124/dmd.120.000274.
A Review of the Important Role of in Pharmacogenomics.
Taylor C, Crosby I, Yip V, Maguire P, Pirmohamed M, Turner R
Genes (Basel). 2020; 11(11).
PMID: 33143137
PMC: 7692531.
DOI: 10.3390/genes11111295.
Domain-Swap Dimerization of CYP51 and a Unique Mechanism of Inactivation by Isavuconazole.
Sharma V, Shing B, Hernandez-Alvarez L, Debnath A, Podust L
Mol Pharmacol. 2020; 98(6):770-780.
PMID: 33008918
PMC: 7674934.
DOI: 10.1124/molpharm.120.000092.
CYP2J2 Molecular Recognition: A New Axis for Therapeutic Design.
Das A, Weigle A, Arnold W, Kim J, Carnevale L, Huff H
Pharmacol Ther. 2020; 215:107601.
PMID: 32534953
PMC: 7773148.
DOI: 10.1016/j.pharmthera.2020.107601.
Analysis of the Deleterious Single-Nucleotide Polymorphisms Associated With Antidepressant Efficacy in Major Depressive Disorder.
Xin J, Yuan M, Peng Y, Wang J
Front Psychiatry. 2020; 11:151.
PMID: 32256400
PMC: 7093583.
DOI: 10.3389/fpsyt.2020.00151.
A Modified Arrhenius Approach to Thermodynamically Study Regioselectivity in Cytochrome P450-Catalyzed Substrate Conversion.
Luirink R, Verkade-Vreeker M, Commandeur J, Geerke D
Chembiochem. 2020; 21(10):1461-1472.
PMID: 31919943
PMC: 7318578.
DOI: 10.1002/cbic.201900751.
Biotransformation, Using Recombinant CYP450-Expressing Baker's Yeast Cells, Identifies a Novel CYP2D6.10 Variant Which Is a Superior Metabolizer of Codeine to Morphine Than the Wild-Type Enzyme.
Williams I, Gatchie L, Bharate S, Chaudhuri B
ACS Omega. 2019; 3(8):8903-8912.
PMID: 31459022
PMC: 6644518.
DOI: 10.1021/acsomega.8b00809.
Pharmacokinetics, excretion and metabolites analysis of DL0410, a dual‑acting cholinesterase inhibitor and histamine‑3 receptor antagonist.
Pang X, Zhao Y, Song J, Kang D, Wu S, Wang L
Mol Med Rep. 2019; 20(2):1103-1112.
PMID: 31173186
PMC: 6625456.
DOI: 10.3892/mmr.2019.10306.
Conformational selection dominates binding of steroids to human cytochrome P450 17A1.
Guengerich F, Wilkey C, Glass S, Reddish M
J Biol Chem. 2019; 294(26):10028-10041.
PMID: 31072872
PMC: 6664176.
DOI: 10.1074/jbc.RA119.008860.
Functional and structural characterisation of common cytochrome P450 2D6 allelic variants-roles of Pro34 and Thr107 in catalysis and inhibition.
Dong A, Ahemad N, Pan Y, Palanisamy U, Yiap B, Ong C
Naunyn Schmiedebergs Arch Pharmacol. 2019; 392(8):1015-1029.
PMID: 31025144
DOI: 10.1007/s00210-019-01651-0.
Coumarins and P450s, Studies Reported to-Date.
Foroozesh M, Sridhar J, Goyal N, Liu J
Molecules. 2019; 24(8).
PMID: 31022888
PMC: 6515222.
DOI: 10.3390/molecules24081620.
Rolapitant Is a Reversible Inhibitor of CYP2D6.
Glass S, Leddy S, Orwin M, Miller G, Furge K, Furge L
Drug Metab Dispos. 2019; 47(6):567-573.
PMID: 30952677
PMC: 6505376.
DOI: 10.1124/dmd.118.085928.
Dynamic Effects of CYP2D6 Genetic Variants in a Set of Poor Metaboliser Patients with Infiltrating Ductal Cancer Under Treatment with Tamoxifen.
Ariza Marquez Y, Briceno I, Aristizabal F, Nino L, Yosa Reyes J
Sci Rep. 2019; 9(1):2521.
PMID: 30792473
PMC: 6385267.
DOI: 10.1038/s41598-018-38340-6.
Microsecond MD simulations of human CYP2D6 wild-type and five allelic variants reveal mechanistic insights on the function.
Don C, Smiesko M
PLoS One. 2018; 13(8):e0202534.
PMID: 30133539
PMC: 6104999.
DOI: 10.1371/journal.pone.0202534.
Kinetic mechanism of time-dependent inhibition of CYP2D6 by 3,4-methylenedioxymethamphetamine (MDMA): Functional heterogeneity of the enzyme and the reversibility of its inactivation.
Rodgers J, Davydova N, Paragas E, Jones J, Davydov D
Biochem Pharmacol. 2018; 156:86-98.
PMID: 30114388
PMC: 6512342.
DOI: 10.1016/j.bcp.2018.08.010.
CYP2D6 Allelic Variants *34, *17-2, *17-3, and *53 and a Thr309Ala Mutant Display Altered Kinetics and NADPH Coupling in Metabolism of Bufuralol and Dextromethorphan and Altered Susceptibility to Inactivation by SCH 66712.
Glass S, Martell C, Oswalt A, Osorio-Vasquez V, Cho C, Hicks M
Drug Metab Dispos. 2018; 46(8):1106-1117.
PMID: 29784728
PMC: 6038030.
DOI: 10.1124/dmd.117.079871.